Clopidogrel remains a cornerstone of secondary stroke prevention, yet its effectiveness hinges on a step that clinicians rarely consider – enzymatic (CYP2C19) hepatic bioactivation. Patients carrying loss-of-function CYP2C19 alleles generate less active drug, blunting platelet inhibition, resulting in measurably higher rates of recurrent stroke. ^{Reference Pan, Chen and Xu1} Despite an Food and Drug Administration boxed warning ² and a substantial evidence base linking this gene–drug interaction to cardiovascular and cerebrovascular outcomes, pharmacogenetic testing remains absent from routine stroke practice.

Rajendram and colleagues ^{Reference Rajendram, Boulos and Dharmakulaseelan3} add important, practical data to this debate. In a prospective cohort of 93 clopidogrel-treated outpatients at a Toronto stroke clinic, self-administered home cheek-swab testing identified 41.9% as intermediate or poor CYP2C19 metabolizers, prompting treating physicians to switch antiplatelet therapy in 72% of these cases. Two features make this study noteworthy beyond its modest size. First, it was conducted in a real-world, ethnically heterogeneous Canadian population, extending observations previously confined largely to Han Chinese cohorts. ^{Reference Wang, Meng and Wang4} The magnitude of loss-of-function prevalence here, and its clinical impact on prescribing, suggests genotype-guided or pharmacogenomic antiplatelet selection should not be merely an Asian-population phenomenon. Second, the study demonstrates that decentralized, patient-collected testing is logistically feasible within a routine outpatient stroke pathway, making it a meaningful step towards scalable implementation.

These findings should be interpreted with appropriate caution. The single-centre design, modest sample size and 49% enrolment response rate raise the possibility of selection bias, and self-reported ethnicity limits the accuracy of sub-group comparisons. Critically, the study was not powered to assess recurrent stroke or bleeding outcomes; thus, the clinical benefit of switching therapy, however biologically plausible, remains inferred rather than proven. The sponsor relationship with the testing vendor also warrants transparent acknowledgement, as the authors appropriately provide, and independent replication would strengthen confidence in the observed yield.

Nonetheless, this work arrives alongside converging evidence ^{Reference Wang, Meng and Wang4,Reference Jung, Song and Kim5} that genotype-informed antiplatelet selection can meaningfully reduce early recurrent events. What is now needed is not further proof of prevalence but pragmatic, adequately powered outcome trials embedded in diverse, real-world populations, alongside cost-effectiveness analyses that can inform guidelines and current practice. Until such data mature, clinicians caring for patients on both acute and long-term clopidogrel should at minimum be aware that accessible genetic testing exists and that a substantial proportion of their patients may be biologically resistant to a drug they are relying on to prevent the next stroke.